Systemic lipopolysaccharide (LPS)-induced microglial activation results in different temporal reduction of CD200 and

Willias Masocha1

  • 1Department of Applied Therapeutics, Faculty of Pharmacy, Kuwait University, Safat, 13110, Kuwait. masocha@hsc.edu.kw

Insights

Lipopolysaccharide (LPS) can lead to chronic microglia activation by disrupting CD200-CD200 receptor (CD200R) balance. Minocycline is ineffective at inhibiting high-dose LPS-induced microglia activation.

Area of Science:

  • Neuroimmunology
  • Microglia biology
  • Neuroinflammation

Background:

  • Microglia are immune cells in the brain, typically quiescent.
  • CD200-CD200 receptor (CD200R) interaction maintains microglial quiescence.
  • Lipopolysaccharide (LPS) is a potent activator of microglia.

Purpose of the Study:

  • To investigate the long-term effects of LPS on microglia activation.
  • To examine the role of the CD200-CD200R pathway in LPS-induced neuroinflammation.
  • To evaluate the efficacy of minocycline in mitigating LPS-induced microglia activation.

Main Methods:

  • Mice were administered LPS (intraperitoneally).
  • MAC-1 mRNA expression (a microglia marker) was measured over time.
  • CD200 and CD200R mRNA levels were analyzed.
  • Minocycline treatment was administered at different LPS doses.

Main Results:

  • MAC-1 mRNA expression remained elevated up to 1 year post-LPS.
  • CD200R mRNA decreased, while CD200 mRNA initially increased then decreased post-LPS.
  • Minocycline failed to prevent MAC-1 mRNA increase with high-dose LPS (5 mg/kg).
  • Minocycline partially reduced MAC-1 mRNA increase with low-dose LPS (0.1 mg/kg).

Conclusions:

  • LPS disrupts the CD200-CD200R equilibrium, potentially causing chronic microglia activation.
  • High-dose LPS-induced microglia activation is not effectively inhibited by minocycline.